Skip to content

Polypill results vary across cardiovascular prevention settings

A pooled analysis found fewer major cardiovascular events in secondary prevention, with no statistically clear reduction in primary or mixed prevention groups.

By 100HP editorialAbstract-based explanation checked

Based on the published abstract. The full paper may contain additional methods, results and limitations.

The 30-second takeaway

Polypills were associated with fewer major adverse cardiovascular events in secondary prevention, aimed at preventing further events. The main analysis found no statistically clear reduction in primary prevention, aimed at preventing a first event, or mixed populations. Results also depended on which combined-event outcome was analyzed, and several individual outcomes showed no clear improvement.

Keep in mind

The evidence includes randomized and observational studies. This abstract-based account cannot resolve unreported follow-up duration or the unexplained distinction between the combined-event outcomes.

THE NUMBERS, WITH CONTEXT

What researchers found

0.80 times the comparison groups’ risk (risk ratio; 95% confidence interval: 0.70–0.92)

Major adverse cardiovascular events in secondary prevention

Polypills versus usual care, single-component therapy or placebo; follow-up not reported. The interval gives a plausible range for the relative risk.

Cardiol Rev, 2026 · Original source ↓

Outcome definitions matter

Polypills combine cardiovascular medicines in a single pill. The review assessed a main combined-event outcome and another called “predefined MACE.” The latter was lower in primary and secondary prevention; the abstract does not explain how the definitions differed.

Individual outcomes were uneven

Cardiovascular deaths and coronary artery events were lower overall, especially in secondary prevention. Stroke, heart failure, peripheral vascular disease and deaths from any cause showed no statistically significant changes. That does not establish equal outcomes.

CHECK THE ORIGINAL

The original publication

The Effectiveness of Polypills for Primary and Secondary Prevention of Major Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis.

Mirhosseini SA, Azami P, Mirzaei A et al.
Cardiol Rev · 2026

PubMed ID
41952094
Record checked

AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.